Efficacy and Safety of OnabotulinumtoxinA in Patients with Urinary Incontinence Due to Neurogenic Detrusor Overactivity: A Randomised, Double Blind, Placebo-Controlled Trial

Yearbook of Urology ◽

10.1016/j.yuro.2012.05.049 ◽

2012 ◽

Vol 2012 ◽

pp. 163-164

Author(s):

E.S. Rovner

Keyword(s):

Urinary Incontinence ◽

Detrusor Overactivity ◽

Controlled Trial ◽

Efficacy And Safety ◽

Neurogenic Detrusor Overactivity ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Efficacy and Safety of OnabotulinumtoxinA in Patients with Urinary Incontinence Due to Neurogenic Detrusor Overactivity: A Randomised, Double-Blind, Placebo-Controlled Trial

European Urology ◽

10.1016/j.eururo.2011.07.002 ◽

2011 ◽

Vol 60 (4) ◽

pp. 742-750 ◽

Author(s):

Francisco Cruz ◽

Sender Herschorn ◽

Philip Aliotta ◽

Mitchell Brin ◽

Catherine Thompson ◽

...

Keyword(s):

Urinary Incontinence ◽

Detrusor Overactivity ◽

Controlled Trial ◽

Efficacy And Safety ◽

Neurogenic Detrusor Overactivity ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.13393973.14762081 ◽

2011 ◽

Author(s):

Eric Rovner ◽

Ahmed El-Zawahry

Keyword(s):

Urinary Incontinence ◽

Detrusor Overactivity ◽

Controlled Trial ◽

Efficacy And Safety ◽

Neurogenic Detrusor Overactivity ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Efficacy and Safety of OnabotulinumtoxinA in Patients with Urinary Incontinence Due to Neurogenic Detrusor Overactivity: Update of the Pivotal Randomised, Double-blind, Placebo-controlled Trials

European Urology Focus ◽

10.1016/j.euf.2016.04.003 ◽

2016 ◽

Vol 2 (3) ◽

pp. 329-331 ◽

Author(s):

Carlos Martins-Silva ◽

Francisco Cruz

Keyword(s):

Urinary Incontinence ◽

Detrusor Overactivity ◽

Controlled Trials ◽

Efficacy And Safety ◽

Neurogenic Detrusor Overactivity ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity-Prospective, randomized, double-blind, placebo-controlled study

Neurourology and Urodynamics ◽

10.1002/nau.23566 ◽

2018 ◽

Vol 37 (7) ◽

pp. 2226-2233 ◽

Author(s):

Jan Krhut ◽

Vladimír Borovička ◽

Karolína Bílková ◽

Radek Sýkora ◽

David Míka ◽

...

Keyword(s):

Detrusor Overactivity ◽

Controlled Study ◽

Efficacy And Safety ◽

Neurogenic Detrusor Overactivity ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1088945.542078 ◽

2007 ◽

Author(s):

Jonathan Schapiro

Keyword(s):

Controlled Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1108987.566149 ◽

2008 ◽

Author(s):

Johann Gudjonsson

Keyword(s):

Monoclonal Antibody ◽

Controlled Trial ◽

Interleukin 12 ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717958672.793516776 ◽

2016 ◽

Author(s):

Robin Spiller

Keyword(s):

Irritable Bowel Syndrome ◽

Controlled Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Irritable Bowel

Download Full-text

Faculty Opinions recommendation of OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718006591.793478312 ◽

2013 ◽

Author(s):

Francisco Cruz

Keyword(s):

Quality Of Life ◽

Urinary Incontinence ◽

Overactive Bladder ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Overactive Bladder Symptoms ◽

Bladder Symptoms

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718524881.793498396 ◽

2014 ◽

Author(s):

David Daikh

Keyword(s):

Ankylosing Spondylitis ◽

Controlled Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Efficacy and Safety of a Monthly Buprenorphine Depot Injection for Opioid Use Disorder: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3228895 ◽

2018 ◽

Author(s):

Barbara R. Haight ◽

Susan M. Learned ◽

Celine M. Laffont ◽

Paul J. Fudala ◽

Yue Zhao ◽

...

Keyword(s):

Controlled Trial ◽

Opioid Use Disorder ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Depot Injection

Download Full-text